This House resolution expresses support for designating September 2026 as National Prostate Cancer Awareness Month to highlight the disease's impact on men in the United States. It calls on the public, interest groups, and affected individuals to promote awareness of screening methods and participate in ceremonies observing the month. The text also urges steps to encourage research into prevention, early detection, and cures, while improving access to quality health care services for prostate cancer treatment.
The REAL Sugar Act would prohibit high fructose corn syrup in foods intended for human consumption by amending the Federal Food, Drug, and Cosmetic Act. This change directly affects food manufacturers and distributors who currently use this sweetener in their products. The prohibition is delayed, applying only to items introduced into interstate commerce two years after the law's enactment. Additionally, the Secretary of Health and Human Services must submit a report to Congress three years later detailing industry reformulation efforts and any necessary regulatory changes.
The Supporting 9-8-8 Crisis Stabilization Act amends Medicaid rules to allow federal funding for specific community-based mental health facilities that were previously excluded from coverage. It defines two new types of eligible sites: crisis receiving and stabilization facilities, which must operate 24/7 with an average stay under 150 hours, and mental health and substance use urgent care centers where individuals can walk in without an appointment. These facilities are required to accept referrals from law enforcement and emergency personnel while prohibiting service denials based on factors like ability to pay or criminal justice history. The bill also directs the Department of Health and Human Services to issue implementation guidance within 180 days and submit a report to Congress one year later analyzing how these changes affect hospital admissions, incarceration rates, and overall crisis response utilization.
The MORE Savings Act aims to reduce financial barriers for individuals seeking treatment for opioid use disorders by eliminating out-of-pocket costs for specific services. For Medicare beneficiaries, it establishes a five-year pilot program in 15 selected states that removes coinsurance, copayments, and deductibles for prescription drugs, behavioral health care, and community recovery support. Additionally, the bill mandates that private group health plans and individual insurance policies cover these same opioid treatments without cost-sharing requirements starting in 2027. Finally, it increases the federal funding match to 90 percent for states providing medication-assisted treatment through Medicaid and allows states to include recovery support services in this coverage.
The Behavioral Health Crisis Services Expansion Act of 2026 mandates that Medicare, Medicaid, and most private health insurance plans cover mental health and substance use crisis response services for individuals experiencing acute episodes. These covered services include care provided by mobile crisis teams, urgent care facilities, and stabilization centers that offer short-term observation without rejecting patients based on their ability to pay or other factors. The legislation also requires ambulance providers to transport individuals in crisis to appropriate facilities and extends coverage requirements to TRICARE, veterans' benefits, federal employee health plans, and the Children's Health Insurance Program. These new coverage mandates generally take effect three years after the bill is enacted, with specific provisions ensuring that financial restrictions on these services are no more severe than those applied to standard medical care.
The Vet CENTERS for Mental Health Act of 2026 requires the Secretary of Veterans Affairs to ensure that every state meets a specific minimum number of mental health treatment centers within one year of enactment. For states in the contiguous United States, this minimum is calculated as the greater of one center per 30,000 square miles of land or one center per 55,000 veterans based on census data. Non-contiguous states and territories must maintain at least one center or match their existing count from January 1, 2020, whichever is higher. To achieve these targets, the Secretary may open new facilities using buildings provided by state, local, or tribal governments, and can establish outstations in place of full centers if multiple additional sites are needed in a single state.
This House resolution supports the goals of National Clinical Nurse Specialist Week, which is observed during the first week of September. It formally recognizes the contributions of these advanced practice nurses to patient care, quality improvement, and workforce development across various healthcare settings. The bill encourages the public to observe the week through appropriate programs and activities. Additionally, it reaffirms the House's commitment to ensuring that Clinical Nurse Specialists are accurately classified in federal labor statistics and supported in health workforce planning.
The 9-8-8 Implementation Act of 2026 expands federal funding and mandates insurance coverage for behavioral health crisis services, directly affecting individuals experiencing mental health or substance use emergencies as well as the providers who serve them. The bill authorizes grants to upgrade local lifeline call centers, build new crisis stabilization facilities, and train a larger workforce of behavioral health professionals. It requires Medicare, Medicaid, private group health plans, TRICARE, and other federal insurance programs to cover crisis response services with financial terms no more restrictive than standard medical care. Additionally, the legislation establishes a federal panel to develop training protocols for 9-1-1 dispatchers to better connect callers to appropriate crisis care rather than law enforcement responses.
The BEDROCK Act directs the Secretary of Commerce to designate a senior official who will lead federal efforts to boost the competitiveness and supply-chain resilience of the U.S. biomanufacturing industry. This official is tasked with identifying barriers to private sector investment, mapping complex regulatory pathways across agencies like the FDA and EPA, and publishing a prioritized action plan to address vulnerabilities in critical inputs such as enzymes and cell lines. The bill also requires the government to create a public web resource that consolidates federal information and designates specific agency points of contact to help businesses navigate commercialization processes. These requirements are set to terminate five years after the law is enacted, with periodic reports submitted to Congress to track progress.
The Advancing Botanical Drug Development Act of 2026 extends the market exclusivity period for new FDA-approved botanical drugs from five years to twelve years. This change directly affects pharmaceutical companies and other sponsors that develop plant-based medicines, providing them with a longer window of protection against generic competitors. The bill aims to offset the high costs and unique manufacturing challenges associated with developing these complex therapies by offering stronger financial incentives. By securing this extended exclusivity, the legislation seeks to encourage private investment in research for multi-target treatments of chronic and age-related diseases.
